{"entity":{"id":"idea-tr1-remote-consent-tele-screening","kind":"idea","name":"Remote consent and tele-screening so the first trial visit is a video call","aka":[],"tldr":"Much of trial screening is paperwork, questions and reviewing scans that already exist. Doing this by video and electronic consent before any travel would let patients decide without a wasted trip.","summary":"Sites adopt electronic consent with teach-back, tele-screening visits reviewing existing imaging and pathology via central read, and remote collection of history and performance status, so in-person attendance is needed only for procedures the protocol genuinely requires. Regulators in the US and EU accept eConsent; adoption in oncology remains low.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)","url":"https://doi.org/10.1093/jnci/djy221"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Sites offering remote consent and screening will convert a higher fraction of referred patients into enrolled patients and shorten the interval from referral to cycle 1 day 1.","rationale":"Screen failure after travel is demoralising and expensive; many failures could be identified from existing records. Remote consent lets patients involve family and take time, which improves comprehension.","test":"Stepped-wedge rollout across a cooperative group's sites; measure referral-to-enrolment conversion and time to first dose before and after.","maturity":"early-clinical","actor":"clinic","cost":"small","horizonYears":1},"route":"/ideas/idea-tr1-remote-consent-tele-screening/","neighbours":{"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"bottleneck":[{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"}],"paper":[{"id":"paper-unger-trial-participation-barriers-jnci-2019","kind":"paper","name":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","route":"/key-papers/paper-unger-trial-participation-barriers-jnci-2019/"}],"roadmap":[{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}]}}